Italia markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
8,49+0,88 (+11,56%)
Alla chiusura: 04:00PM EST
8,47 -0,02 (-0,24%)
Dopo ore: 07:59PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente7,61
Denaro8,38 x 900
Lettera8,46 x 1100
Min-Max giorno7,40 - 8,50
Intervallo di 52 settimane2,87 - 11,70
Media Volume5.730.980
Beta (5 anni mensile)0,98
Rapporto PE (ttm)N/D
EPS (ttm)-10,43
Prossima data utili02 mar 2023 - 06 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,33
  • GlobeNewswire

    Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy

    The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLOFLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to provide multiple health plans with access to an innovative, outcomes-based agreement for ZYNTEGLO® (betibeglogene autotem

  • GlobeNewswire

    Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil